Effects Of Sodium Glucose Cotranspoter 2 Inhibitors On Heart And Kidneys In Fabry Disease Patients

Inclusion Criteria * Age: 18-70 years * Patients with genetically confirmed Fabry disease. * On treatment with Enzyme Replacement Therapy (ERT). * ERT or chaperone therapy at stable dose for at least 3 last months * Albuminuria \>35 mg/day and/or proteinuria \>150 mg/day * eGFR ≥25 mL/min/1.73 m2 * On a stable dose of an ACEi, ARB or renin receptors blockers for at least 4 weeks prior to randomization * Sufficient command of German language. * Signed and dated informed consent. * Known cardiac association of FD Exclusion Criteria: * Known hypersensitivity, allergy or contraindications to dapagliflozin. * Diagnosis of type 1 or type 2 diabetes mellitus * Patients with any disease (other than Fabry disease) affecting the heart and the kidnys. * History of kidney transplantation. * Active malignancy. * Use of the co-interventional treatments (Aldosterone antagonists, Continuous use of NSAIDs or systemic steroids) within 6 weeks of screening will not be allowed. * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: 1. History of active inflammatory bowel disease within the last six months; 2. Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; 3. Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months; 4. Pancreatic injury or pancreatitis within the last six months; 5. Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at the screening visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt; * Subject who, in the assessment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data. * Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing. * Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. * Women who are pregnant or breast feeding; intention to become pregnant during the course of the study, lack of safe contraception. * Patients with known or suspected non-compliance, drug or alcohol abuse, including Marijuana cigarettes. * Participation in another study with investigational drugs within the 30 days preceding and during the present study. * Enrolment of the investigator, his/her family members, employees and other dependent persons. * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant.